Penserra Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Penserra Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,450	Closed	-$1.91M	–	1094
2025 Q4	$1.91M	Buy	+10,450	New	+$1.46M	0.02%	336
2025 Q2	–	Sell	-19,112	Closed	-$2.23M	–	1031
2025 Q1	$2.23M	Buy	+19,112	New	+$2.18M	0.04%	288
2021 Q4	–	Sell	-865	Closed	-$28K	–	1382
2021 Q3	$28K	Buy	865 +10	+1%	+$390	﹤0.01%	1194
2021 Q2	$57K	Buy	855 +15	+2%	+$900	﹤0.01%	965
2021 Q1	$47K	Sell	840 -15	-2%	-$1.05K	﹤0.01%	822
2020 Q4	$69K	Buy	855 +535	+167%	+$40K	﹤0.01%	645
2020 Q3	$22K	Buy	+320	New	+$24.9K	﹤0.01%	723

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Penserra Capital Management's AXSM Position: Q1 2026 in Review

Penserra Capital Management sold out of Axsome Therapeutics (AXSM) in Q1 2026, closing a stake of 10,450 shares — an estimated $1.91M sold.

Penserra Capital Management first reported a position in AXSM in Q3 2020 and held it in 7 quarters. The position peaked at $2.23M in Q1 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Penserra Capital Management reported no remaining Axsome Therapeutics position as of Q1 2026 after selling out during the quarter.
Penserra Capital Management sold 10,450 Axsome Therapeutics shares in Q1 2026, an estimated $1.91M.
Penserra Capital Management first reported a position in Axsome Therapeutics in Q3 2020 and held it in 7 quarters.
Penserra Capital Management's Axsome Therapeutics position peaked at $2.23M in Q1 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Penserra Capital Management's 13F filing for Q1 2026, filed 11 May 2026.